TY - JOUR
T1 - Antigens to viral capsid and non-capsid proteins are present in brain tissues and antibodies in sera of Theiler's virus-infected mice
AU - Cameron, K.
AU - Zhang, X.
AU - Seal, B.
AU - Rodriguez, M.
AU - Njenga, M. K.
N1 - Funding Information:
This research was supported by Office of Vice President for Research and Dean of the graduate School of the University of Minnesota. We thank Joyce Bennett for assistance in nucleotide sequencing, and Michael Murtaugh for technical support.
PY - 2001
Y1 - 2001
N2 - Recombinant proteins to the LP, VP1, VP2, VP3, VP4, 2A, 2B, 2C, 3A, and 3D genes of Theiler's murine encephalomyelitis virus (TMEV) were generated and antibodies were produced against them for use in analysis of the TMEV epitopes responsible for eliciting the antibody responses observed during acute and chronic disease. Antibodies against recombinant VP1, VP2, and VP3 recognized the corresponding proteins from purified TMEV particles. In immunohistochemical analysis, antibodies against recombinant capsid (VP1, VP2, and VP3), and non-capsid (2A, 2C, 3A) proteins were reactive with PO-2D cells (astrocytes) infected with TMEV in vitro and with brain tissues of acutely infected mice. Antibodies against VP4, 2B, and 3D antigens were not reactive with corresponding viral proteins in infected astrocytes cells or brain tissues, but they reacted with TMEV precursor proteins produced during the early viral replication phase. Sera from SJL/J mice infected with TMEV acutely (14 days) and chronically (45 days) reacted with VP1, VP2, VP4, 2A, and 2C proteins. In an in vitro assay for neutralization, only anti-VP1 antibodies neutralized TMEV infection. These findings suggest that both capsid and non-capsid proteins of TMEV play a role in the immunopathology of the TMEV disease in the central nervous system.
AB - Recombinant proteins to the LP, VP1, VP2, VP3, VP4, 2A, 2B, 2C, 3A, and 3D genes of Theiler's murine encephalomyelitis virus (TMEV) were generated and antibodies were produced against them for use in analysis of the TMEV epitopes responsible for eliciting the antibody responses observed during acute and chronic disease. Antibodies against recombinant VP1, VP2, and VP3 recognized the corresponding proteins from purified TMEV particles. In immunohistochemical analysis, antibodies against recombinant capsid (VP1, VP2, and VP3), and non-capsid (2A, 2C, 3A) proteins were reactive with PO-2D cells (astrocytes) infected with TMEV in vitro and with brain tissues of acutely infected mice. Antibodies against VP4, 2B, and 3D antigens were not reactive with corresponding viral proteins in infected astrocytes cells or brain tissues, but they reacted with TMEV precursor proteins produced during the early viral replication phase. Sera from SJL/J mice infected with TMEV acutely (14 days) and chronically (45 days) reacted with VP1, VP2, VP4, 2A, and 2C proteins. In an in vitro assay for neutralization, only anti-VP1 antibodies neutralized TMEV infection. These findings suggest that both capsid and non-capsid proteins of TMEV play a role in the immunopathology of the TMEV disease in the central nervous system.
KW - Antibody
KW - Encephalitis
KW - Recombinant proteins
KW - Theiler's murine encephalomyelitis virus
UR - http://www.scopus.com/inward/record.url?scp=0035155961&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035155961&partnerID=8YFLogxK
U2 - 10.1016/S0166-0934(00)00246-9
DO - 10.1016/S0166-0934(00)00246-9
M3 - Article
C2 - 11164481
AN - SCOPUS:0035155961
SN - 0166-0934
VL - 91
SP - 11
EP - 19
JO - Journal of Virological Methods
JF - Journal of Virological Methods
IS - 1
ER -